Previous 10 | Next 10 |
home / stock / esaly / esaly news
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500) TOKYO, Mar 9, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been certified as the Health and Productivity Management Outstanding Organization in the large ...
Stifel has downgraded shares of Biogen (NASDAQ:BIIB) to but from hold amidst several factors, notable concerns over the likelihood that Alzheimer's treatment lecanemab wins approval. The firm cut its price target to $223 from $304 (~8% upside based on Monday's close). Analyst Paul Matteis sai...
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma TOKYO, Mar 7, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kina...
Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALY) began submission of application data in Japan aimed at getting an early approval of their Alzheimer's disease (AD) therapy lecanemab. Eisai began a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application...
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab TOKYO, Mar 4, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen...
Biogen (NASDAQ:BIIB) shares are trading higher in the pre-market Thursday after RBC Capital Markets upgraded the battered Alzheimer’s drug developer, citing an improving risk-reward setup following a survey of physicians. The analysts led by Brian Abrahams argue that Biogen (BIIB) has ...
Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma TOKYO and KENILWORTH, N.J., Feb 25, 2022 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside...
The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2021 Q3 earnings call. For further details see: Eisai Co., Ltd. 2021 Q3 - Results - Earnings Call Presentation
Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Conference Call February 3, 2022, 2:00 AM ET Company Participants Dr. Ryohei Yanagi - Chief Financial Officer Ivan Cheung - President, Neurology Business Group Dr. Takashi Owa - President, Oncology Business Group Teruyuki Masaka - In-charge, Business P...
Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021 TOKYO, Feb 1, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as the winner of the Tokyo Governor Prize for Corporate Governance of the Year 2021, which is an award p...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...